Stereotaxis Inc (STXS)

AMEX · Healthcare · Medical Instruments & Supplies · USA

Stereotaxis Inc is a micro cap company (market value under $300 million) in the Medical Instruments & Supplies industry.

Stereotaxis produces robotic equipment and software platforms for interventional laboratories using proprietary Robotic Magnetic Navigation technology that employs computer-controlled magnetic fields to direct catheter tips during procedures. The company's offerings include Genesis RMN and GenesisX RMN Systems, Odyssey and Synchrony solutions, and interventional devices such as Map-iT catheters, serving hospitals and physicians globally.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Stereotaxis Inc stock.

Our verdict on STXS

Overvalued: intrinsic value $0.07 per share, market price $0.88, margin of safety -1154.9% (as of 2026-11-17).

A 0.5x revenue multiple, discounted for its losses, values the shares at $0.07; the price of $0.88 is 1155% above that value.

ETFs with the most weight in STXS

8 more funds hold it; the full list is part of the paid plan.

More on STXS

Browse

Peers in Medical Instruments & Supplies

All 52 Medical Instruments & Supplies stocks

Cheaper than STXS in Medical Instruments & Supplies

22 more in this industry show a wider margin of safety.

Is STXS undervalued or overvalued?

STXS is overvalued (as of the 2026-11-17 close). A 0.5x revenue multiple, discounted for its losses, values the shares at $0.07; the price of $0.88 is 1155% above that value.

What is the intrinsic value of STXS?

$0.07 per share (as of the 2026-11-17 close), against a market price of $0.88. That is a margin of safety of -1154.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.